Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms VESTA
- Sponsors AbbVie
- 28 Jul 2017 Planned End Date changed from 1 Mar 2018 to 28 Mar 2018.
- 10 May 2017 This trial has been completed in Estonia.
- 03 Apr 2017 Planned End Date changed from 1 Apr 2017 to 1 Mar 2018.